Medical Pharmacology: Chapter: General Anesthesia — Chapter 14 -- Module: GA-03 — CNS and Cardiovascular Effects of Inhalational Anesthetics

Chapter: General Anesthesia — Chapter 14 — Module: GA-03 — CNS and Cardiovascular Effects of Inhalational Anesthetics
Tier: Core Concepts — Foundational Knowledge (22 questions)

1. Inhalational anesthetic agents produce reversible loss of consciousness primarily by acting on which of the following molecular targets?

A) Blocking voltage-gated sodium channels in peripheral sensory neurons
B) Potentiating gamma-aminobutyric acid type A (GABA-A) receptors — the main inhibitory receptor in the brain — and inhibiting excitatory N-methyl-D-aspartate (NMDA) receptors
C) Activating mu-opioid receptors in the brainstem and limbic system
D) Blocking nicotinic acetylcholine receptors at the neuromuscular junction
E) Inhibiting carbonic anhydrase in cerebral cortical neurons

ANSWER: B

Rationale:

Option B is correct. Inhalational agents produce CNS depression through two complementary mechanisms: potentiation of GABA-A receptors (the principal inhibitory neurotransmitter receptors in the brain) and inhibition of NMDA receptors (a major class of excitatory receptors). Together these actions suppress cortical and subcortical neuronal excitability, producing dose-dependent EEG slowing and ultimately unconsciousness.

Option A: Option A is incorrect because peripheral sodium channel blockade describes local anesthetic mechanisms, not general anesthetic mechanisms; volatile agents do interact with some voltage-gated channels centrally but this is not the primary mechanism.
Option C: Option C is incorrect because mu-opioid receptor activation describes opioid analgesics — inhalational agents do not produce their primary anesthetic effect through opioid receptors.
Option D: Option D is incorrect because neuromuscular junction nicotinic receptor blockade is the mechanism of neuromuscular blocking agents, not inhalational anesthetics.
Option E: Option E is incorrect because carbonic anhydrase inhibition is the mechanism of drugs like acetazolamide and is not relevant to the anesthetic effect of inhaled agents.

2. Among the inhalational anesthetic agents, which one produces the greatest increase in cerebral blood flow (CBF) at equivalent minimum alveolar concentration (MAC) fractions — the dose needed to prevent movement in 50% of patients?

A) Sevoflurane
B) Isoflurane
C) Desflurane
D) Halothane
E) Nitrous oxide

ANSWER: D

Rationale:

Option D is correct. Halothane produces the greatest increase in CBF among the volatile anesthetic agents at equivalent MAC fractions, with increases of 200% or more above baseline reported at 2 MAC in some studies. This reflects halothane's potent direct cerebral vasodilatory effect, which exceeds that of the newer agents at comparable doses.

Option A: Option A is incorrect because sevoflurane produces a more modest CBF increase — typically 20 to 40% above baseline at 1 MAC in normocapnic patients — substantially less than halothane.
Option B: Option B is incorrect because isoflurane also produces modest CBF increases (20 to 40% at 1 MAC) significantly less than halothane; isoflurane is actually the preferred volatile agent for deliberate hypotension or cerebral protection because of its greater CMRO2 suppression relative to its CBF effect.
Option C: Option C is incorrect because desflurane's CBF effects are intermediate and similar to isoflurane, not the greatest among the agents.
Option E: Option E is incorrect because nitrous oxide produces only a modest increase in CBF and CMRO2 when used alone; though this increase is paradoxical given its overall depressant properties, it is substantially smaller in magnitude than halothane's CBF effect.

3. Volatile anesthetic agents can reduce the brain's oxygen consumption (cerebral metabolic rate for oxygen, or CMRO2) as anesthetic depth increases. At the point of burst suppression — a pattern on the electroencephalogram (EEG) where electrical activity alternates between brief bursts and flat periods — approximately what percentage reduction in CMRO2 has been achieved, and why can deeper anesthesia not reduce it further?

A) Approximately 50 to 60% reduction; the remaining oxygen consumption supports housekeeping functions such as ion pump activity and membrane maintenance that are not suppressible by anesthetic agents
B) Approximately 80 to 90% reduction; the remaining oxygen consumption is used exclusively by glial cells, which are resistant to volatile anesthetics
C) Approximately 20 to 30% reduction; burst suppression represents only light anesthetic depth and deeper anesthesia continues to reduce CMRO2 substantially
D) Approximately 50 to 60% reduction; the remaining oxygen consumption is entirely eliminated by increasing the volatile agent concentration above 2 MAC
E) Complete elimination of CMRO2 (100% reduction); burst suppression represents the maximum achievable metabolic protection and no further oxygen is consumed

ANSWER: A

Rationale:

Option A is correct. At burst suppression, CMRO2 is reduced by approximately 50 to 60% from awake baseline. This represents the maximum suppression achievable through electrical inactivation of neuronal activity. The remaining 40% of cerebral oxygen consumption is devoted to housekeeping metabolic processes — principally the activity of ion pumps (particularly the Na/K-ATPase that maintains neuronal resting potential) and membrane maintenance. These processes are not driven by neuronal firing and therefore cannot be further reduced by suppressing electrical activity. Increasing anesthetic depth beyond burst suppression does not provide additional metabolic protection, a clinically important ceiling effect.

Option B: Option B is incorrect because the remaining consumption is not glial-exclusive; it represents basal cellular maintenance across all brain cell types, and 80 to 90% reduction is not achieved even at burst suppression.
Option C: Option C is incorrect because burst suppression reflects deep anesthetic suppression of neuronal electrical activity, and the 50 to 60% figure is accurate — 20 to 30% would represent only mild suppression.
Option D: Option D is incorrect because the remaining oxygen consumption is not eliminated by increasing the anesthetic concentration above 2 MAC — the ceiling is a metabolic floor set by non-electrical cellular processes, not a pharmacological limitation that can be overcome with higher doses.
Option E: Option E is incorrect because complete CMRO2 elimination would require cessation of all cellular metabolic activity, which is incompatible with cell survival; volatile anesthetics cannot achieve this.

4. A neuroanesthesia team is planning an elective craniotomy for resection of a cortical seizure focus in a patient with a known seizure disorder. Which inhalational anesthetic agent must be avoided because it is the only volatile agent with clinically documented epileptogenic potential at higher concentrations?

A) Isoflurane
B) Sevoflurane
C) Enflurane
D) Desflurane
E) Nitrous oxide

ANSWER: C

Rationale:

Option C is correct. Enflurane is the only volatile anesthetic agent with clinically documented epileptogenic potential. At inspired concentrations above approximately 2 MAC, particularly when combined with hypocapnia (low PaCO2, which lowers seizure threshold by causing cerebral vasoconstriction and neuronal alkalosis), enflurane produces high-amplitude EEG spike-and-wave complexes and can induce generalized tonic-clonic seizures even in patients without a pre-existing seizure disorder. This property renders enflurane formally contraindicated in patients with epilepsy and unsuitable for cases requiring cortical monitoring.

Option A: Option A is incorrect because isoflurane does not possess meaningful epileptogenic potential; at high doses it produces burst suppression, which is an antiepileptiform pattern, making it suitable for use even in patients with seizure disorders.
Option B: Option B is incorrect because sevoflurane, while associated with isolated reports of EEG spike activity during induction at high concentrations in some pediatric patients, is not classified as an epileptogenic agent for clinical purposes, and clinically overt seizures attributable to sevoflurane are exceedingly rare.
Option D: Option D is incorrect because desflurane has no clinically significant epileptogenic potential and is not contraindicated in seizure patients on this basis.
Option E: Option E is incorrect because nitrous oxide has no epileptogenic activity and may actually provide mild anticonvulsant effect through its NMDA receptor antagonism.

5. The Monro-Kellie doctrine is the foundational principle governing intracranial pressure dynamics. Which of the following correctly states this principle and explains why volatile anesthetic agents carry risk in patients with intracranial mass lesions?

A) The brain generates its own intracranial pressure independently of blood volume, so anesthetic-induced vasodilation only becomes dangerous when the agent causes direct neurotoxicity
B) The blood-brain barrier separates the intracranial compartment from systemic circulation, preventing any volatile anesthetic from affecting intracranial pressure unless the barrier is disrupted
C) Intracranial pressure is determined solely by cerebrospinal fluid production rate and can be normalized by reducing CSF production with acetazolamide, regardless of anesthetic choice
D) The cranial vault is a semi-rigid compartment that expands gradually to accommodate volume increases, so anesthetic-induced vasodilation is only dangerous during the first few minutes of induction
E) The cranial vault is a rigid compartment of fixed total volume containing brain parenchyma, cerebrospinal fluid (CSF), and blood; because these components must sum to a constant, any increase in intracranial blood volume caused by volatile-agent-induced vasodilation will raise intracranial pressure in patients with reduced intracranial compliance

ANSWER: E

Rationale:

Option E is correct. The Monro-Kellie doctrine holds that the cranial vault is a rigid, fixed-volume compartment whose contents — brain parenchyma, CSF, and intravascular blood — must sum to a constant total volume. In patients with normal intracranial compliance, a modest increase in intracranial blood volume (as produced by volatile-anesthetic-induced vasodilation) can be temporarily compensated by displacement of CSF into the spinal subarachnoid space. However, in patients with reduced intracranial compliance — such as those with mass lesions, traumatic brain injury, cerebral edema, or hydrocephalus — these compensatory mechanisms are exhausted, and even a small increase in blood volume produces a disproportionate rise in intracranial pressure.

Option A: Option A is incorrect because volatile agents do not need to cross the blood-brain barrier to affect ICP — their systemic vasodilatory and cerebrovascular effects raise intracranial blood volume regardless of neurotoxicity, and the blood-brain barrier is not the relevant constraint.
Option B: Option B is incorrect for the same reason; volatile agents reach the brain and exert direct cerebrovascular effects; the blood-brain barrier does not prevent ICP changes mediated by increased CBF.
Option C: Option C is incorrect because ICP is determined by all three compartments, not CSF production alone; acetazolamide has only a modest and slow ICP-lowering effect and does not neutralize the acute ICP risks of volatile-agent-induced vasodilation.
Option D: Option D is incorrect because the cranial vault is not semi-rigid and does not expand to accommodate volume increases in adults; the compliance buffer is finite and is provided by CSF displacement, not skull expansion.

6. During induction of anesthesia in a patient with a large supratentorial tumor and signs of elevated intracranial pressure (ICP), the anesthesiologist immediately initiates controlled hyperventilation after intubation. What is the mechanism by which this maneuver lowers ICP, and what is its primary limitation during prolonged use?

A) Hyperventilation increases oxygen delivery to the brain, reducing reactive vasodilation; its limitation is that increased FiO2 requirements may cause pulmonary oxygen toxicity over time
B) Hyperventilation reduces arterial CO2 (PaCO2), which causes cerebral vasoconstriction by altering perivascular pH; its limitation is that the vasoconstrictive effect wanes over 4 to 6 hours as CSF bicarbonate adapts, and rebound ICP elevation may occur upon normalization of ventilation
C) Hyperventilation increases intrathoracic pressure, reducing venous return to the brain and lowering cerebral blood volume; its limitation is that it simultaneously reduces cardiac output and systemic blood pressure
D) Hyperventilation alkalinizes the blood, which directly reduces brain water content by an osmotic effect; its limitation is that metabolic alkalosis impairs oxygen release from hemoglobin
E) Hyperventilation lowers nitrogen tension in the blood, allowing absorption of intracranial gas collections; its limitation is that it does not affect the blood component of intracranial volume

ANSWER: B

Rationale:

Option B is correct. Controlled hyperventilation lowers PaCO2, which causes cerebral vasoconstriction through CO2-mediated changes in perivascular pH. A reduction in PaCO2 of 10 mmHg below baseline reduces CBF by approximately 20 to 30% and produces a corresponding reduction in intracranial blood volume and ICP. The effect is rapid — onset within seconds to minutes — making hyperventilation the fastest available maneuver for acute ICP reduction in the operating room. However, the vasoconstrictive effect is not sustained: over 4 to 6 hours, CSF bicarbonate is actively adjusted to restore perivascular pH toward normal, attenuating the vasoconstrictive response. Additionally, upon normalization of ventilation, rebound ICP elevation may occur if CSF bicarbonate adaptation has already taken place. Aggressive hypocapnia below 30 mmHg also risks cerebral ischemia.

Option A: Option A is incorrect because the mechanism involves CO2-mediated vasoconstriction, not oxygen delivery effects, and pulmonary oxygen toxicity is not a relevant limitation for intraoperative use.
Option C: Option C is incorrect because the ICP-lowering effect of hyperventilation is mediated by cerebral vasoconstriction from low PaCO2, not by increased intrathoracic pressure reducing venous return; positive-pressure ventilation does reduce venous return but that is a side effect, not the primary ICP mechanism.
Option D: Option D is incorrect because the mechanism is not osmotic alkalinization of blood; changes in blood pH lower ICP through vascular, not osmotic, effects on brain water.
Option E: Option E is incorrect because nitrogen tension is not clinically relevant to ICP management; intracranial gas collections are a concern with nitrous oxide, not with hyperventilation per se.

7. A neurosurgeon plans temporary occlusion of a cerebral artery during an intracranial aneurysm repair. The anesthesiologist selects a volatile agent specifically to maximize the brain's tolerance of the temporary ischemia by producing an isoelectric EEG — a completely flat electroencephalogram indicating maximal electrical suppression. Which agent is most commonly chosen for this purpose, and why?

A) Isoflurane, because it reduces CMRO2 to a greater degree than halothane at equivalent MAC fractions and can produce complete electrical silence (isoelectric EEG) at clinically achievable concentrations, maximizing the ischemia-tolerable interval
B) Halothane, because it produces the greatest cerebral vasodilation among the volatile agents, increasing oxygen delivery to ischemic regions during vessel occlusion
C) Sevoflurane, because it has the fastest onset and offset among the volatile agents, allowing precise titration of the ischemic protection window
D) Desflurane, because it produces the most profound CMRO2 suppression among all inhalational agents and is the only agent capable of achieving isoelectric EEG
E) Nitrous oxide, because its NMDA receptor antagonism (blocking a type of excitatory receptor) provides direct neuroprotection independent of metabolic suppression

ANSWER: A

Rationale:

Option A is correct. Isoflurane is the most extensively studied volatile agent for cerebral ischemia protection in the neurosurgical context. It reduces CMRO2 to a greater degree than halothane at equivalent MAC fractions and, critically, can produce complete electrical silence — an isoelectric EEG — at clinically achievable concentrations. This maximal EEG suppression translates to maximal reduction of the electrical (neuronal activity) component of cerebral oxygen consumption, extending the period that the brain can tolerate ischemia before irreversible injury occurs. This property is specifically exploited during deliberate hypotension or temporary vessel occlusion in aneurysm surgery.

Option B: Option B is incorrect because halothane's primary effect relevant to ischemia protection would be metabolic suppression, not vasodilation; vasodilation in already-ischemic regions is not beneficial and halothane is not chosen for this purpose because it provides inferior CMRO2 suppression compared to isoflurane.
Option C: Option C is incorrect because sevoflurane's onset/offset properties are not the relevant consideration for ischemia protection; the relevant property is depth of metabolic suppression, and sevoflurane and isoflurane are broadly comparable in this regard — isoflurane is simply the more established agent for this specific application.
Option D: Option D is incorrect because desflurane does not produce more profound CMRO2 suppression than isoflurane; its effects are broadly similar at equivalent MAC fractions, and it is not considered superior to isoflurane for deliberate metabolic suppression in this setting.
Option E: Option E is incorrect because nitrous oxide is not suitable for ischemia protection during aneurysm surgery — it increases CMRO2 rather than reducing it, increases CBF, and should generally be avoided in neurosurgical patients; its NMDA antagonism does not provide meaningful clinical neuroprotection in this context.

8. An anesthesiologist is planning rapid sequence induction for a patient with a known intracranial mass lesion and signs of elevated intracranial pressure (ICP). Which of the following best describes the concern with using succinylcholine — a depolarizing neuromuscular blocking agent that causes all muscles to contract briefly before paralysis — in this patient, and what is the preferred alternative?

A) Succinylcholine causes prolonged bradycardia that reduces cerebral perfusion pressure; the preferred alternative is vecuronium at standard intubating doses
B) Succinylcholine is metabolized by plasma cholinesterase into potentially neurotoxic byproducts that directly increase ICP by disrupting the blood-brain barrier; the preferred alternative is cisatracurium
C) Succinylcholine causes histamine release that dilates cerebral vessels and raises ICP; the preferred alternative is pancuronium, which has vasoconstrictive properties
D) Succinylcholine causes a transient ICP increase through muscle fasciculation-induced afferent neural input that briefly increases cerebral activity and CBF; the preferred alternative in elective elevated-ICP cases is rocuronium at 1.2 mg/kg, which approaches succinylcholine's onset speed while avoiding fasciculations
E) Succinylcholine directly blocks cerebral NMDA receptors, causing paradoxical cerebral excitation and raising ICP; the preferred alternative is any nondepolarizing agent at any dose

ANSWER: D

Rationale:

Option D is correct. Succinylcholine causes whole-body muscle fasciculations as it depolarizes all neuromuscular junctions simultaneously. These fasciculations generate afferent neural input that transiently increases cerebral activity and CBF, producing a brief (approximately 2 to 5 minute) rise in ICP of typically 5 to 10 mmHg. While modest in absolute terms, this transient rise may be clinically significant in a patient with severely elevated ICP and exhausted intracranial compliance, potentially risking herniation. For elective neurosurgical procedures, succinylcholine is therefore best avoided in favor of rocuronium at 1.2 mg/kg, which provides rapid intubating conditions (onset within 60 to 90 seconds) without causing fasciculations. However, in a true airway emergency where aspiration or failed intubation risk outweighs the ICP concern, succinylcholine remains appropriate.

Option A: Option A is incorrect because succinylcholine causes transient bradycardia via muscarinic effects in some patients but this is not the ICP mechanism, and vecuronium at standard doses does not approach succinylcholine's onset speed.
Option B: Option B is incorrect because succinylcholine is not neurotoxic and does not disrupt the blood-brain barrier; its ICP effect is entirely mediated through peripheral fasciculations.
Option C: Option C is incorrect because histamine release is associated with agents like atracurium and morphine, not succinylcholine specifically; and pancuronium is the least desirable agent in neurosurgical patients because its vagolytic properties cause tachycardia and hypertension that increase CBF and can worsen ICP.
Option E: Option E is incorrect because succinylcholine does not block NMDA receptors; its mechanism is depolarizing blockade at the nicotinic acetylcholine receptor at the neuromuscular junction, not central receptor activity.

9. All inhalational anesthetic agents reduce mean arterial pressure (MAP) in a dose-dependent fashion, but the mechanism differs between agents. Which of the following correctly distinguishes the mechanism of MAP reduction for halothane versus isoflurane, and explains why this distinction matters for patients with impaired cardiac function?

A) Halothane reduces MAP primarily through peripheral vasodilation, while isoflurane reduces MAP through myocardial depression; patients with impaired cardiac function tolerate halothane better because vasodilation preserves contractility
B) Both halothane and isoflurane reduce MAP exclusively through peripheral vasodilation; the distinction lies in the degree of vasodilation, with halothane being more potent
C) Halothane reduces MAP primarily through myocardial depression, reducing cardiac output while maintaining or increasing systemic vascular resistance; isoflurane reduces MAP primarily through peripheral vasodilation, reducing systemic vascular resistance while cardiac output is relatively preserved through baroreceptor-mediated heart rate compensation
D) Halothane reduces MAP through direct coronary vasodilation reducing afterload; isoflurane reduces MAP through inhibition of baroreceptor reflexes that normally maintain blood pressure
E) Both agents reduce MAP equally through GABA-A receptor-mediated depression of the vasomotor center in the brainstem; the difference in clinical effect is determined entirely by the rate of induction, not the mechanism

ANSWER: C

Rationale:

Option C is correct. The mechanistic distinction between halothane and isoflurane is clinically fundamental. Halothane is primarily a myocardial depressant: it reduces cardiac output by depressing contractility and stroke volume, while systemic vascular resistance is maintained or even increased. Isoflurane (and similarly sevoflurane and desflurane at stable concentrations) reduces MAP primarily through peripheral vasodilation — lowering systemic vascular resistance — while cardiac output is relatively preserved because baroreceptor-mediated reflex tachycardia partially compensates. For patients with impaired myocardial function, isoflurane-induced MAP reduction (which preserves cardiac output by reducing afterload) is better tolerated than halothane-induced MAP reduction (which does not — it further reduces an already-compromised cardiac output). This distinction directly guides agent selection in patients with known left ventricular dysfunction.

Option A: Option A is incorrect because it reverses the mechanisms: halothane is the myocardial depressant and isoflurane is the vasodilator, not vice versa.
Option B: Option B is incorrect because halothane and isoflurane do not share the same mechanism — halothane's primary effect is myocardial depression, not vasodilation.
Option D: Option D is incorrect because coronary vasodilation is a secondary effect of both agents, not the mechanism of MAP reduction, and baroreceptor inhibition is not the primary mechanism of isoflurane's cardiovascular effects.
Option E: Option E is incorrect because the cardiovascular effects of volatile agents are mediated through direct effects on cardiac muscle and vascular smooth muscle, not solely through brainstem vasomotor center depression; the mechanistic difference between agents is real and not reducible to rate of induction.

10. During maintenance of anesthesia with desflurane in a patient with known coronary artery disease, the anesthesiologist abruptly increases the inspired concentration from below 1 MAC to above 1 MAC. Within minutes, the patient develops marked tachycardia and hypertension. Which of the following best explains this response, and why is this patient population particularly at risk?

A) The rapid concentration increase caused reflex bradycardia that was followed by a compensatory hypertensive overshoot; patients with coronary artery disease are at risk because bradycardia impairs diastolic filling
B) The abrupt increase triggered GABA-A receptor downregulation in the cardiovascular control centers, producing paradoxical sympathetic activation; this is unique to desflurane because of its low blood-gas solubility
C) The high inspired concentration of desflurane caused direct coronary vasospasm, triggering an anginal reflex that activates the sympathetic nervous system through pain pathways
D) Desflurane at all concentrations produces dose-dependent tachycardia and hypertension through direct cardiac stimulation; the effect is simply more visible when the concentration is increased rapidly
E) Rapid increases in desflurane concentration trigger a marked sympathetic discharge — releasing catecholamines — producing tachycardia and hypertension that are poorly tolerated by patients with coronary artery disease because the resulting increase in myocardial oxygen demand may exceed supply in territories with fixed stenotic vessels

ANSWER: E

Rationale:

Option E is correct. Desflurane has a unique property not shared by other volatile agents: abrupt increases in its inspired concentration — particularly from below 1 MAC to above 1 MAC — trigger a marked sympathetic discharge. This releases catecholamines, producing tachycardia and hypertension that can be severe. At stable maintenance concentrations, desflurane's cardiovascular profile is similar to isoflurane. This sympathetic surge response is particularly dangerous in patients with coronary artery disease because the combination of tachycardia (which reduces diastolic filling time and coronary perfusion) and hypertension (which increases myocardial wall stress and oxygen demand) can precipitate myocardial ischemia in territories supplied by stenotic vessels with limited flow reserve. To avoid this, desflurane concentration should be increased in small increments and supplemented with opioids or alpha-2 agonists such as dexmedetomidine or clonidine to blunt the sympathetic response.

Option A: Option A is incorrect because the response is sympathetic activation (tachycardia and hypertension), not bradycardia followed by overshoot; reflex bradycardia is not the mechanism of desflurane's sympathetic surge.
Option B: Option B is incorrect because the mechanism is not GABA-A receptor downregulation; the sympathetic surge is a peripheral airway and central nervous system irritant-mediated response to rapid desflurane concentration increases, not a receptor regulation phenomenon.
Option C: Option C is incorrect because direct coronary vasospasm is not the mechanism; the cardiovascular response is mediated by sympathetic catecholamine release, not coronary spasm triggering pain pathways.
Option D: Option D is incorrect because tachycardia and hypertension are not a stable dose-dependent effect of desflurane at all concentrations — at stable concentrations desflurane behaves similarly to isoflurane; the sympathetic surge is specifically associated with rapid concentration increases, not with steady-state maintenance.

11. An orthopedic surgeon plans a complex spinal deformity correction requiring intraoperative neurophysiological monitoring (IONM) of motor evoked potentials (MEPs) — signals generated by electrically stimulating the brain and recording muscle responses to detect spinal cord injury in real time. The anesthesiologist knows that the planned volatile anesthetic maintenance technique will need to be modified. Which of the following best describes the pharmacological constraint and the required anesthetic technique?

A) Volatile agents are acceptable for MEP monitoring provided the concentration is kept above 1.5 MAC; below this threshold MEPs become unreliable due to insufficient anesthetic depth
B) Volatile anesthetic agents suppress MEP amplitude in a dose-dependent fashion — reducing it by 50% or more at 0.5 MAC and frequently abolishing MEPs entirely at 1.0 MAC — making reliable MEP monitoring impossible during standard volatile maintenance; total intravenous anesthesia (TIVA) with propofol and remifentanil is the required technique
C) Volatile agents enhance MEP amplitude by reducing background neuronal noise, making MEP monitoring more sensitive; the constraint is that nitrous oxide must be avoided because it abolishes MEP signals entirely
D) MEP monitoring is unaffected by volatile anesthetic concentration below 2 MAC; the relevant pharmacological constraint is that neuromuscular blocking agents must be avoided entirely during the procedure
E) Somatosensory evoked potentials (SSEPs) are more sensitive to volatile agents than MEPs and are routinely abandoned during volatile maintenance; MEPs are the more robust signal and can be reliably recorded at any volatile concentration

ANSWER: B

Rationale:

Option B is correct. Motor evoked potentials (MEPs) are generated by transcranial electrical stimulation and recorded from peripheral muscles; they are exquisitely sensitive to volatile anesthetic agents. At concentrations of 0.5 MAC, MEP amplitude is reduced by 50% or more. At 1.0 MAC, MEPs are frequently unrecordable. This extreme sensitivity makes reliable MEP monitoring impossible during standard volatile agent maintenance. Total intravenous anesthesia (TIVA) with propofol and remifentanil is therefore the required technique for cases in which MEP monitoring is planned. Nitrous oxide also suppresses MEPs and is avoided in these cases. Additionally, neuromuscular blockade must be carefully managed: complete blockade abolishes MEPs because motor units must be intact to generate peripheral recordings; typically one or two twitches of the train-of-four are permitted.

Option A: Option A is incorrect because higher volatile concentrations produce greater MEP suppression, not less; the relationship is dose-dependent in the direction of increasing suppression, not a threshold below which MEPs become unreliable.
Option C: Option C is incorrect because volatile agents suppress, not enhance, MEP signals, and nitrous oxide suppresses — rather than abolishes — MEPs; the constraint is not limited to nitrous oxide.
Option D: Option D is incorrect because MEPs are suppressed at concentrations well below 2 MAC (already severely suppressed at 0.5 to 1.0 MAC); and while neuromuscular blockade does affect MEPs, complete avoidance of all blocking agents is not required — partial blockade (one to two twitches) is acceptable.
Option E: Option E is incorrect because it reverses the relative sensitivities: MEPs are more sensitive to volatile agents than SSEPs, not less; SSEPs can often be monitored at volatile concentrations of 0.5 MAC or below, while MEPs at that concentration are already substantially suppressed.

12. Mannitol (an osmotic diuretic — a drug that uses a concentration gradient to draw water out of tissues) is administered at 1 g/kg IV at the beginning of a supratentorial tumor resection to reduce brain bulk. Which of the following correctly describes the primary mechanism by which mannitol reduces intracranial pressure (ICP), an important limitation of this mechanism, and the standard serum osmolality threshold above which repeat dosing carries increased risk of kidney injury?

A) Mannitol's primary mechanism is osmotic: by elevating serum osmolality, it draws free water from brain parenchyma into the intravascular compartment along the osmotic gradient, reducing brain water content; this mechanism requires an intact blood-brain barrier for full efficacy and may paradoxically worsen edema in areas where the barrier is disrupted; repeat dosing is limited when serum osmolality exceeds approximately 320 mOsm/kg
B) Mannitol's primary mechanism is loop diuresis: it inhibits the Na-K-2Cl cotransporter in the kidney, producing vigorous diuresis that lowers total body water and reduces brain edema; its limitation is that it simultaneously depletes potassium, requiring continuous electrolyte replacement; repeat dosing is limited when serum potassium falls below 3.0 mEq/L
C) Mannitol's primary mechanism is direct cerebral vasoconstriction: it reduces CBF by increasing blood viscosity, lowering intracranial blood volume; its limitation is that it raises systemic blood pressure unpredictably; repeat dosing is limited when systolic blood pressure exceeds 160 mmHg
D) Mannitol's primary mechanism is CSF production inhibition: it blocks carbonic anhydrase in the choroid plexus, reducing the rate at which CSF is made; its effect is maximal within 5 minutes of administration; repeat dosing is limited when serum bicarbonate falls below 18 mEq/L
E) Mannitol's primary mechanism is blood-brain barrier stabilization: it cross-links tight junction proteins, reducing permeability and preventing further fluid extravasation; its limitation is that it only works in cytotoxic edema (swelling from direct cell injury), not vasogenic edema; repeat dosing is limited when serum sodium exceeds 155 mEq/L

ANSWER: A

Rationale:

Option A is correct. Mannitol is a large, membrane-impermeant sugar alcohol that remains in the intravascular compartment. By elevating serum osmolality, it establishes an osmotic gradient that draws free water out of brain parenchyma — down its concentration gradient — into the blood. This reduces brain water content and volume, thereby reducing ICP. The mechanism is maximal within 15 to 30 minutes of administration and sustained for 90 to 120 minutes. Critically, this osmotic mechanism requires an intact blood-brain barrier: in areas where the barrier is disrupted (as by tumor, contusion, or infarction), mannitol may enter the tissue itself and paradoxically worsen edema over time. Serum osmolality should be monitored with repeated dosing; values exceeding 320 mOsm/kg are associated with increased risk of acute kidney injury.

Option B: Option B is incorrect because the described mechanism is that of furosemide (loop diuresis via Na-K-2Cl cotransporter inhibition), not mannitol; mannitol does not work by inhibiting this cotransporter.
Option C: Option C is incorrect because mannitol acutely reduces blood viscosity (a rheological effect that transiently improves microcirculatory flow) rather than increasing it; direct cerebral vasoconstriction and blood pressure elevation are not its primary mechanisms.
Option D: Option D is incorrect because carbonic anhydrase inhibition and CSF production reduction describe the mechanism of acetazolamide, not mannitol; mannitol's onset is rapid (not 5 minutes) and its primary mechanism is osmotic, not CSF-related.
Option E: Option E is incorrect because blood-brain barrier stabilization is not the mechanism of mannitol; the described effect on tight junction proteins is not how mannitol works, and mannitol is effective primarily in vasogenic edema (where the blood-brain barrier is intact enough to maintain the osmotic gradient), not exclusively in cytotoxic edema.

13. A patient with traumatic brain injury and a measured ICP of 28 mmHg (normal is below 20 mmHg) requires emergency craniotomy. The anesthesiologist opts for total intravenous anesthesia (TIVA) rather than a volatile agent-based technique. Which of the following best explains the pharmacological rationale for this choice?

A) Propofol used in TIVA is the only anesthetic agent that prevents intraoperative seizures; volatile agents are proconvulsant and would worsen the neurological injury in this patient
B) Propofol produces reliable bronchodilation, which reduces ventilatory pressures and secondarily lowers intrathoracic pressure, improving cerebral venous drainage and reducing ICP
C) Propofol has a faster onset than any volatile agent, allowing more rapid induction; in a trauma patient with elevated ICP, every second of delay in achieving unconsciousness worsens outcome
D) Propofol reduces CMRO2 and CBF without causing the cerebral vasodilation associated with volatile agents, and at clinical infusion rates it preserves cerebral autoregulation better than volatile agents; these properties make it the preferred agent when intracranial compliance is already severely compromised
E) Propofol is the only intravenous agent that does not raise ICP; all other intravenous agents including ketamine, midazolam, and fentanyl significantly raise ICP and must be avoided in this patient

ANSWER: D

Rationale:

Option D is correct. The key pharmacological rationale for preferring propofol-based TIVA over volatile agents in patients with severely elevated ICP rests on two properties. First, propofol reduces CMRO2 and CBF without causing cerebral vasodilation — unlike volatile agents, which reduce CMRO2 but simultaneously vasodilate the cerebral vasculature, increasing intracranial blood volume and ICP. Second, propofol at clinical infusion rates preserves cerebral autoregulation — the ability of the brain to maintain stable CBF across a range of perfusion pressures — better than volatile agents, which impair autoregulation in a dose-dependent fashion. In a patient with severely reduced intracranial compliance and elevated ICP, this combination of properties (metabolic suppression without vasodilation, preserved autoregulation) makes TIVA the superior technique.

Option A: Option A is incorrect because the primary rationale for choosing propofol is not seizure prevention; while some volatile agents have proconvulsant potential (notably enflurane), the modern agents isoflurane, sevoflurane, and desflurane are not clinically proconvulsant, and seizure avoidance is not the reason propofol is preferred for elevated ICP management.
Option B: Option B is incorrect because propofol's bronchodilation is not the mechanism of its ICP benefit; reducing intrathoracic pressure via bronchodilation is not a significant contributor to ICP management and is not the reason TIVA is selected.
Option C: Option C is incorrect because onset speed is not the primary rationale for choosing TIVA over volatile anesthesia in this patient; both techniques can achieve rapid induction, and the choice is driven by the cerebrovascular pharmacology, not induction speed.
Option E: Option E is incorrect because it overstates the contraindications of other agents; fentanyl and midazolam do not significantly raise ICP at clinical doses, and the statement that all other intravenous agents raise ICP is incorrect.

14. A surgeon infiltrates a local anesthetic solution containing epinephrine (a catecholamine — a class of compounds including adrenaline that stimulate the heart and blood vessels) for hemostasis during a procedure performed under halothane anesthesia. The anesthesiologist warns that the dose of epinephrine must be strictly limited. Which of the following best explains the pharmacological basis for this concern?

A) Halothane inhibits the reuptake of epinephrine by sympathetic nerve terminals, causing prolonged and exaggerated systemic vasoconstriction that raises blood pressure to dangerous levels
B) Halothane blocks beta-1 adrenergic receptors in the heart, preventing the normal tachycardic response to epinephrine and instead causing reflex bradycardia that may progress to asystole
C) Halothane sensitizes the myocardium to catecholamine-induced arrhythmias through mechanisms involving calcium overload and altered automaticity of Purkinje fibers (specialized cardiac conduction cells); the threshold for epinephrine-induced ventricular arrhythmias under halothane is approximately 1.5 to 2 mcg/kg, compared to 7 to 10 mcg/kg under isoflurane
D) Halothane is metabolized to reactive intermediates that react with epinephrine in the circulation, forming a toxic compound that directly depolarizes ventricular myocytes
E) Halothane causes coronary vasospasm in the presence of catecholamines by displacing nitric oxide from coronary endothelial cells, producing ischemia-driven ventricular irritability

ANSWER: C

Rationale:

Option C is correct. Halothane sensitizes the myocardium to catecholamine-induced arrhythmias through mechanisms that involve calcium overload in myocytes and altered automaticity of Purkinje fibers — the specialized conduction cells that initiate ventricular beats. In the presence of halothane, doses of epinephrine that would be innocuous under isoflurane or sevoflurane anesthesia can trigger ventricular ectopy, bigeminy (every other beat is a premature ventricular contraction), and in severe cases ventricular fibrillation. The threshold dose for epinephrine-induced arrhythmias under halothane is approximately 1.5 to 2 mcg/kg, compared to 7 to 10 mcg/kg under isoflurane — a four- to five-fold difference that is clinically highly significant when infiltrating epinephrine-containing local anesthetics. This is a well-established and unique property of halothane among the volatile agents.

Option A: Option A is incorrect because halothane does not inhibit epinephrine reuptake; its arrhythmogenic sensitization is mediated through direct myocardial effects on ion channels and automaticity, not through prolonged catecholamine action.
Option B: Option B is incorrect because halothane does not block beta-1 receptors; it actually tends to produce bradycardia through depression of sinoatrial node automaticity and sensitization to vagal tone, not through beta-receptor blockade, and the concern with epinephrine is arrhythmia, not asystole.
Option D: Option D is incorrect because halothane metabolites do not react with circulating epinephrine to form a toxic compound; the arrhythmogenic sensitization is a pharmacodynamic interaction, not a pharmacokinetic one.
Option E: Option E is incorrect because halothane-induced coronary vasospasm triggered by nitric oxide displacement is not an established mechanism; the myocardial sensitization is a direct electrophysiological effect, not an ischemia-mediated phenomenon.

15. Among the volatile halogenated anesthetic agents, which produces the greatest reduction in systemic vascular resistance (SVR — the resistance the heart must pump against) at equivalent MAC fractions, and what is the clinical implication for patients who are already vasodilated, such as those with septic shock?

A) Halothane produces the greatest SVR reduction because its potent myocardial depression reflexively triggers maximal vasodilation through baroreceptor compensation; patients with septic shock tolerate this well because their vasculature is already dilated
B) Desflurane produces the greatest SVR reduction among volatile agents; this is why it is the preferred agent for deliberate hypotensive anesthesia during major vascular surgery
C) Sevoflurane and desflurane produce equal and maximal SVR reduction; the clinical implication is that both must be avoided in patients with aortic stenosis because afterload reduction unmasks the fixed outflow obstruction
D) All volatile agents produce identical SVR reduction at equivalent MAC fractions; the difference in blood pressure effect between agents is entirely explained by their different degrees of myocardial depression
E) Isoflurane is the most potent peripheral vasodilator among the volatile agents, producing the greatest reduction in SVR at equivalent MAC fractions; in patients already vasodilated — such as those in septic shock or hepatic failure — further SVR reduction by isoflurane may precipitate profound hypotension

ANSWER: E

Rationale:

Option E is correct. Isoflurane is the most potent peripheral vasodilator among the volatile anesthetic agents, producing the greatest reduction in systemic vascular resistance at equivalent MAC fractions. Sevoflurane and desflurane produce intermediate reductions in SVR, and halothane produces the least peripheral vasodilation (its predominant cardiovascular mechanism being myocardial depression rather than vasodilation). In patients with normal or elevated baseline vascular resistance, isoflurane-induced SVR reduction lowers afterload and may actually preserve cardiac output. However, in patients who are already vasodilated — as in septic shock, hepatic failure, or other distributive shock states — the vasculature has lost its normal compensatory reserve, and further SVR reduction by isoflurane can precipitate profound hypotension that cannot be adequately compensated by increased cardiac output.

Option A: Option A is incorrect because halothane is the least peripheral vasodilator among the volatile agents; its blood pressure reduction is mediated primarily through myocardial depression, and the compensatory baroreceptor response to myocardial depression is attenuated, not enhanced.
Option B: Option B is incorrect because isoflurane, not desflurane, is the most potent peripheral vasodilator; desflurane produces intermediate SVR reduction, and deliberate hypotensive anesthesia is most commonly managed with multiple agents, not desflurane specifically.
Option C: Option C is incorrect because sevoflurane and desflurane do not produce equal SVR reduction, and the specific clinical concern with aortic stenosis and afterload reduction, while real, is not the distinguishing feature of the concept being tested here.
Option D: Option D is incorrect because volatile agents do not produce identical SVR reduction at equivalent MAC fractions — the degree of vasodilation versus myocardial depression varies meaningfully and clinically significantly among agents, which is precisely why agent selection matters in cardiovascular disease.

16. A 58-year-old patient presents with a large metastatic brain tumor surrounded by extensive cerebral edema. The neurosurgeon pre-treats the patient with dexamethasone for several days before the planned craniotomy. Which of the following best explains why dexamethasone is effective in this scenario but would not be expected to help a patient with cerebral edema caused by a large ischemic stroke?

A) Dexamethasone is a potent osmotic agent that draws water directly out of edematous brain tissue through an albumin-binding mechanism; ischemic stroke edema is predominantly intravascular and inaccessible to this mechanism
B) Dexamethasone reduces vasogenic edema — the type caused by blood-brain barrier disruption allowing protein-rich fluid to leak into brain tissue — by decreasing barrier permeability and reducing tumor-associated inflammatory mediator production; it is not effective for cytotoxic edema, the type caused by ischemic cell swelling where cells swell from failed ion pumps rather than from fluid leaking through a disrupted barrier
C) Dexamethasone reduces ICP by stimulating CSF reabsorption through the arachnoid granulations; ischemic stroke disrupts these granulations, rendering dexamethasone ineffective in that setting
D) Dexamethasone blocks prostaglandin synthesis through COX inhibition, preventing the inflammatory vasodilation that drives cerebral edema in tumor cases; ischemic edema is prostaglandin-independent
E) Dexamethasone works by inducing cerebral vasoconstriction through glucocorticoid receptors on vascular smooth muscle; ischemic stroke causes maximal vasodilation that cannot be overcome by dexamethasone

ANSWER: B

Rationale:

Option B is correct. The distinction between vasogenic and cytotoxic cerebral edema is fundamental to understanding when corticosteroids are and are not effective. Vasogenic edema — the type surrounding brain tumors, abscesses, and other mass lesions — results from disruption of the blood-brain barrier, allowing protein-rich fluid to leak from blood vessels into the extracellular space of the brain parenchyma. Dexamethasone reduces this type of edema by decreasing blood-brain barrier permeability and suppressing inflammatory mediator production by the tumor. The onset of effect is slow (hours to days), which is why pre-operative treatment for several days before surgery is standard. Cytotoxic edema — as occurs in ischemic stroke — results from failure of the Na/K-ATPase ion pump in ischemic cells, causing intracellular sodium and water accumulation. The blood-brain barrier may be intact; the problem is intracellular swelling, not extracellular fluid leakage. Dexamethasone cannot reverse this pump failure and is not effective for cytotoxic edema; it is not recommended for ischemic stroke.

Option A: Option A is incorrect because dexamethasone is not an osmotic agent and does not work through an albumin-binding mechanism; its mechanism is anti-inflammatory, reducing barrier permeability.
Option C: Option C is incorrect because dexamethasone does not work by stimulating CSF reabsorption through arachnoid granulations; its primary action is on vascular permeability in the context of tumor-related barrier disruption.
Option D: Option D is incorrect because while corticosteroids do suppress prostaglandin synthesis through induction of lipocortin and inhibition of phospholipase A2 (which is upstream of COX), the primary relevant mechanism for brain edema reduction is blood-brain barrier stabilization, not simply anti-prostaglandin effects.
Option E: Option E is incorrect because dexamethasone does not work primarily through direct cerebrovascular smooth muscle constriction via glucocorticoid receptors; its ICP-reducing effect is mediated through reduced fluid extravasation, not vasomotor tone.

17. During maintenance anesthesia for a supratentorial tumor resection, the anesthesiologist deliberately avoids adding nitrous oxide (N2O) to the inhaled gas mixture, even though it could reduce the required concentration of the volatile agent. Which of the following best explains the rationale for avoiding nitrous oxide in this setting?

A) Nitrous oxide increases both cerebral blood flow (CBF) and cerebral metabolic rate for oxygen (CMRO2) when used alone — paradoxically for a depressant agent — likely through sympathetic activation; it can also expand any intracranial gas collection inadvertently introduced during surgery; both properties make it undesirable in neurosurgical patients where ICP control is a priority
B) Nitrous oxide produces irreversible inhibition of NMDA receptors in the cerebral cortex that persists for several hours after discontinuation, impairing neurological examination in the immediate postoperative period
C) Nitrous oxide causes profound cerebral vasodilation that is more severe than any halogenated volatile agent, making ICP uncontrollable in any patient with a brain tumor regardless of other interventions
D) Nitrous oxide is avoided because it reduces the inspired oxygen fraction (FiO2), making it impossible to maintain adequate arterial oxygenation during neurosurgical procedures that require frequent periods of controlled hypotension
E) Nitrous oxide competitively inhibits the action of intraoperative osmotic diuretics like mannitol by reducing serum osmolality through a dilutional effect, preventing effective brain relaxation

ANSWER: A

Rationale:

Option A is correct. Nitrous oxide, despite being a CNS depressant at the clinical level, produces a paradoxical modest increase in CBF and CMRO2 when used alone, an effect thought to reflect sympathetic nervous system activation. In the context of neurosurgical anesthesia where maintaining low CBF and ICP is a priority, this property makes nitrous oxide an undesirable component of the technique. Additionally, nitrous oxide is 34 times more soluble in blood than nitrogen, allowing it to diffuse rapidly into any closed gas-containing space — including any small collection of intracranial air that may be inadvertently introduced during surgery. This can cause significant expansion of the gas collection, with potentially dangerous ICP elevation. For these reasons, nitrous oxide is generally avoided in neurosurgical patients. When used as part of a combined technique with a volatile agent (where its MAC-sparing effect allows reduction of the volatile agent), the net CBF effect depends on the balance between these opposing factors.

Option B: Option B is incorrect because nitrous oxide does not cause irreversible NMDA receptor inhibition; its NMDA antagonism is fully reversible and clears within minutes of discontinuation.
Option C: Option C is incorrect because nitrous oxide's effect on CBF is modest, not profound, and the characterization as more severe than any halogenated agent is incorrect; halothane produces far greater CBF increases than nitrous oxide at equivalent doses.
Option D: Option D is incorrect because nitrous oxide is typically administered at 50 to 70% concentration, which does reduce FiO2 but not to levels that make oxygenation impossible in healthy lungs; controlled hypotension during neurosurgery is not the relevant concern, and maintaining adequate FiO2 during N2O use is managed by adjusting concentrations accordingly.
Option E: Option E is incorrect because nitrous oxide does not interact with or inhibit mannitol's osmotic mechanism; serum osmolality is determined by dissolved solutes in blood, not by inhaled gases, and this interaction does not exist.

18. An anesthesiologist is planning the induction sequence for a patient with a known brain tumor, elevated intracranial pressure, and a full stomach requiring rapid sequence induction (RSI — a technique where medications are given rapidly to achieve intubating conditions before the patient can aspirate stomach contents). Which neuromuscular blocking agent is most appropriate for this patient, and why?

A) Succinylcholine at the standard dose of 1.5 mg/kg, because RSI mandates succinylcholine in all patients with full stomachs and the transient ICP increase it causes is clinically negligible in all circumstances
B) Vecuronium at 0.1 mg/kg (standard intubating dose), because it does not cause fasciculations and has a well-established safety profile in neurosurgical patients without the cardiovascular side effects of succinylcholine
C) Pancuronium at 0.1 mg/kg, because its vagolytic properties (blocking vagal slowing of the heart) prevent the bradycardia associated with laryngoscopy, which can reduce cardiac output and lower cerebral perfusion pressure
D) Rocuronium at 1.2 mg/kg, because at this high dose it approaches succinylcholine's onset speed (intubating conditions within 60 to 90 seconds), does not cause fasciculations and the associated ICP increase, and can be rapidly reversed with sugammadex (a drug that encapsulates and inactivates rocuronium) if needed
E) Atracurium at 0.5 mg/kg, because its Hofmann elimination — a process where the drug breaks down spontaneously in the body without requiring liver or kidney function — makes it the safest agent in patients with neurological injury affecting autonomic reflexes

ANSWER: D

Rationale:

Option D is correct. In a patient with elevated ICP requiring rapid sequence induction, the ideal neuromuscular blocking agent must provide rapid onset of intubating conditions (to minimize the time the patient is at risk for aspiration) while avoiding fasciculations (which transiently raise ICP). Rocuronium at 1.2 mg/kg — approximately twice the standard intubating dose — fulfills both requirements. At this dose, onset of intubating conditions occurs within 60 to 90 seconds, approaching succinylcholine's onset speed. Unlike succinylcholine, rocuronium does not cause fasciculations and does not raise ICP. Additionally, if reversal is urgently needed (such as for cannot-intubate, cannot-oxygenate), sugammadex can rapidly encapsulate and inactivate the rocuronium, restoring neuromuscular function. This combination of rapid onset, no fasciculations, and reversibility makes high-dose rocuronium the preferred agent for RSI in patients with elevated ICP.

Option A: Option A is incorrect because succinylcholine's transient ICP increase is not negligible in all circumstances; in a patient with severely compromised intracranial compliance and markedly elevated ICP, even a 5 to 10 mmHg transient rise may risk herniation, and the guideline explicitly states that succinylcholine is best avoided for elective neurosurgical procedures in this setting.
Option B: Option B is incorrect because vecuronium at standard intubating doses (0.1 mg/kg) has an onset of 3 to 5 minutes — far too slow for RSI; rapid sequence induction requires onset within 60 to 90 seconds.
Option C: Option C is incorrect because pancuronium is the least desirable steroidal agent in neurosurgical patients: its vagolytic properties cause tachycardia and hypertension, which increase CBF and can worsen ICP — the opposite of what is desired.
Option E: Option E is incorrect because atracurium at standard doses has an onset of 2 to 3 minutes, which is too slow for RSI; additionally, atracurium is associated with histamine release and produces the metabolite laudanosine, a potential CNS stimulant, making it suboptimal for neurosurgical cases.

19. A patient with a high-grade glioma (brain tumor) involving Broca's area — the region of the brain responsible for producing speech — requires surgical resection with intraoperative language mapping to preserve speech function. The surgical team plans an awake craniotomy. Which of the following best describes the preferred anesthetic technique and the pharmacological rationale for it?

A) Ketamine infusion with local scalp block, because ketamine's dissociative properties allow the patient to respond to commands while simultaneously providing complete analgesia; its sympathomimetic effects maintain blood pressure without vasopressors during the awake phase
B) Sevoflurane at 0.5 MAC with remifentanil infusion, because low-dose volatile anesthesia provides adequate sedation while preserving enough cortical function for language mapping; sevoflurane's rapid offset allows awakening within minutes of discontinuation
C) The asleep-awake-asleep technique using propofol and remifentanil infusions: propofol provides titratable sedation/anesthesia for skin incision, craniotomy, and closure; remifentanil provides analgesia during stimulating phases and clears within minutes of discontinuation, allowing rapid and reliable awakening for the cortical mapping phase; a local anesthetic scalp block is essential for pain control during pin placement and incision
D) Dexmedetomidine infusion as the sole anesthetic agent throughout the entire procedure, because its ability to produce cooperative sedation without respiratory depression makes it uniquely suited to awake craniotomy and eliminates the need for any other anesthetic agents
E) Midazolam and fentanyl in intermittent boluses, because benzodiazepine sedation with opioid analgesia is the most reliable method of producing cooperative patient behavior during cortical mapping, with antagonists (flumazenil and naloxone) available to rapidly reverse sedation if needed

ANSWER: C

Rationale:

Option C is correct. The asleep-awake-asleep technique is the most widely used approach for awake craniotomy requiring language or motor mapping. Propofol and remifentanil, administered by target-controlled or weight-based infusion, are the agents of choice because of their complementary pharmacological properties. Propofol provides titratable sedation — readily adjusted between deep anesthesia for the stimulating phases (pin fixation, skin incision, bone flap, dural opening) and light sedation or wakefulness for the mapping phase — with smooth, predictable onset and offset. Remifentanil, an ultra-short-acting opioid with a context-sensitive half-time of approximately 3 to 4 minutes regardless of infusion duration, provides reliable analgesia during the painful phases and clears within minutes of dose reduction, allowing rapid recovery without residual opioid sedation impairing language testing. Local anesthetic scalp block of multiple nerves (greater occipital, supraorbital, auriculotemporal, and others) is essential for pain control at pin fixation and incision sites.

Option A: Option A is incorrect because ketamine, while useful in some settings, is not the preferred agent for awake craniotomy — its dissociative properties are not consistently compatible with the precise cooperative language testing required, it can increase ICP through sympathomimetic-mediated CBF increases, and it may produce dysphoria or emergence phenomena that interfere with mapping.
Option B: Option B is incorrect because even low-dose volatile anesthesia suppresses cortical function unpredictably and cannot be reliably titrated to the precise level of cooperation needed for language mapping; volatile agents are not suitable for awake craniotomy techniques.
Option D: Option D is incorrect because dexmedetomidine is increasingly used as an adjunct or sole sedative in awake craniotomy and does have the described properties, but the question asks for the preferred technique — propofol-remifentanil remains the most established and widely used combination, with dexmedetomidine as a supplement or alternative.
Option E: Option E is incorrect because midazolam-fentanyl combinations produce sedation that is unpredictable in depth and difficult to reverse reliably; the availability of antagonists (flumazenil and naloxone) is noted but reversal agents add complexity and risk, and this combination does not offer the smooth titratable control of propofol-remifentanil.

20. Cerebral autoregulation is the brain's intrinsic mechanism for maintaining a relatively constant cerebral blood flow (CBF) despite changes in blood pressure, operating normally across a cerebral perfusion pressure (CPP) range of approximately 50 to 150 mmHg. Which of the following correctly describes how volatile anesthetic agents affect this mechanism and what the clinical consequence is during deep inhalational anesthesia?

A) Volatile agents enhance cerebral autoregulation by stabilizing cerebrovascular smooth muscle tone through GABA-A receptor activation in vessel walls; this is clinically beneficial in neurosurgical patients where blood pressure fluctuates during surgery
B) Volatile agents preserve cerebral autoregulation completely at concentrations below 1 MAC and abolish it completely above 1 MAC; the transition is abrupt and can be predicted by the EEG pattern
C) Volatile agents shift the autoregulatory curve to the right, requiring higher blood pressures to maintain the same CBF; clinically this means hypotension is better tolerated under volatile anesthesia because the brain is protected at lower perfusion pressures
D) Volatile agents have no effect on cerebral autoregulation; any change in CBF during volatile anesthesia is explained entirely by CO2 reactivity changes, not by loss of pressure-flow regulation
E) Volatile agents impair cerebral autoregulation in a dose-dependent fashion, shifting the relationship between CPP and CBF toward a pressure-passive state at concentrations of 1 MAC or above; clinically this means CBF becomes more directly dependent on MAP — hypotension causes proportional CBF reductions, and hypertension causes proportional CBF increases with potentially elevated ICP

ANSWER: E

Rationale:

Option E is correct. Volatile anesthetic agents impair cerebral autoregulation in a dose-dependent manner. At concentrations of 1 MAC or above, all volatile agents substantially attenuate the cerebrovascular resistance adjustments that normally maintain stable CBF across a range of perfusion pressures. The result is a shift toward a pressure-passive state: CBF becomes more directly dependent on MAP. The clinical consequences are bidirectional and important — hypotension during deep inhalational anesthesia causes proportional reductions in CBF (and thus risk of cerebral hypoperfusion), while hypertension causes proportional CBF increases that may elevate ICP in patients with reduced intracranial compliance. This is one of the key rationales for preferring propofol-based TIVA in patients with compromised intracranial compliance, because propofol at clinical infusion rates preserves cerebral autoregulation better than volatile agents.

Option A: Option A is incorrect because volatile agents impair, not enhance, cerebral autoregulation; GABA-A receptor activation in vessel walls is not the mechanism of autoregulatory function, and the claim that this is beneficial to neurosurgical patients is incorrect.
Option B: Option B is incorrect because the impairment of autoregulation by volatile agents is graded and dose-dependent, not a sharp threshold at 1 MAC; there is no abrupt transition, and the EEG does not reliably predict the autoregulatory status.
Option C: Option C is incorrect because the autoregulatory curve is not shifted to the right (which would imply a need for higher pressures to maintain flow) — volatile agents reduce the range of pressures over which autoregulation operates effectively, making CBF pressure-passive, which is worse tolerance of hypotension, not better.
Option D: Option D is incorrect because CO2 reactivity (the change in CBF per change in PaCO2) and cerebral autoregulation (the change in CBF per change in CPP) are distinct mechanisms; volatile agents impair autoregulation independently of their effects on CO2 reactivity, which is actually preserved during inhalational anesthesia.

21. During one-lung ventilation for a thoracic surgical procedure, the anesthesiologist switches from isoflurane to a propofol infusion for maintenance. The rationale involves hypoxic pulmonary vasoconstriction (HPV) — a physiological reflex in which lung blood vessels constrict in areas of poor ventilation, diverting blood flow to better-ventilated lung regions to maintain oxygenation. Which of the following best explains why propofol is preferred over volatile agents for maintenance during one-lung ventilation?

A) Propofol produces direct bronchodilation in the ventilated lung, increasing its compliance and allowing higher tidal volumes that compensate for the blood flow mismatch created by one-lung ventilation
B) Volatile anesthetic agents inhibit hypoxic pulmonary vasoconstriction (HPV) in a dose-dependent fashion, worsening intrapulmonary shunting and ventilation-perfusion mismatch; propofol does not inhibit HPV and is therefore preferred for maintenance during one-lung ventilation when oxygenation is marginal
C) Propofol reduces pulmonary arterial pressure more effectively than volatile agents, improving right ventricular function during one-lung ventilation when pulmonary vascular resistance is elevated by surgical manipulation of the lung
D) Volatile agents cause bronchospasm in the non-ventilated lung during one-lung ventilation by stimulating irritant receptors in collapsed airways; propofol prevents this reflex through central nervous system depression of the cough reflex
E) Propofol is preferred because it does not cross into the non-ventilated lung through the tracheobronchial tree, preventing pharmacological effects in the collapsed lung that would otherwise interfere with surgical dissection

ANSWER: B

Rationale:

Option B is correct. Hypoxic pulmonary vasoconstriction is a critical physiological mechanism that maintains ventilation-perfusion matching by diverting pulmonary blood flow away from poorly ventilated or collapsed lung regions toward well-ventilated regions. During one-lung ventilation, HPV reduces blood flow to the collapsed, non-ventilated lung, limiting the intrapulmonary shunt fraction and maintaining arterial oxygenation. All volatile anesthetic agents — isoflurane, sevoflurane, and desflurane — inhibit HPV in a dose-dependent fashion at clinically used concentrations. This inhibition worsens intrapulmonary shunting and ventilation-perfusion mismatch, contributing to intraoperative hypoxemia. Propofol does not inhibit HPV and therefore allows the physiological vasoconstriction to continue operating in the non-ventilated lung, preserving arterial oxygenation. This is the specific pharmacological rationale for preferring propofol-based TIVA for thoracic surgery requiring one-lung ventilation, particularly when oxygenation is already marginal.

Option A: Option A is incorrect because propofol does have mild bronchodilatory properties, but this is not the primary rationale for preferring it over volatile agents during one-lung ventilation; the key issue is HPV inhibition, not bronchial compliance.
Option C: Option C is incorrect because the primary rationale is HPV preservation, not pulmonary arterial pressure reduction; while volatile agents do have some effects on pulmonary vascular resistance, this is not the mechanism driving the preference for propofol in this specific clinical context.
Option D: Option D is incorrect because volatile agents do not cause bronchospasm in the non-ventilated lung via irritant receptor stimulation; volatile agents are actually bronchodilators in the ventilated lung, and the cough reflex is not the relevant mechanism.
Option E: Option E is incorrect because propofol is an intravenous agent that reaches the lungs through the pulmonary circulation like all other drugs; the premise that it does not cross into the non-ventilated lung is physiologically incoherent and is not the rationale for its use.

22. Experimental and clinical data suggest that certain volatile anesthetic agents — particularly isoflurane and sevoflurane — can reduce cardiac injury during coronary artery bypass surgery through a phenomenon called anesthetic-induced preconditioning. Which of the following best describes the proposed mechanism of this protective effect and the clinical evidence supporting it?

A) Volatile anesthetic agents activate mitochondrial ATP-sensitive potassium (KATP) channels — channels that open when cellular energy is low and help protect cells from injury — through adenosine receptor signaling; this mechanism reduces ischemia-reperfusion injury, and clinical trials in cardiac surgical patients have demonstrated reductions in cardiac troponin release (a marker of heart muscle damage) with isoflurane and sevoflurane compared to total intravenous anesthesia
B) Volatile agents precondition the heart by causing mild, reversible myocardial depression before bypass, reducing the metabolic demand of the heart during the ischemic period of cardioplegia and allowing more complete recovery upon reperfusion
C) Volatile agents prevent reperfusion injury by inhibiting neutrophil migration into the myocardium through downregulation of adhesion molecules on coronary endothelial cells; this is the primary mechanism, and the effect requires at least 4 hours of continuous volatile exposure before bypass
D) Anesthetic preconditioning is mediated entirely through volatile-agent-induced reduction in systemic vascular resistance, which lowers left ventricular wall stress and reduces myocardial oxygen demand throughout the perioperative period, independent of any direct cellular mechanism
E) Volatile agents precondition the myocardium by permanently upregulating antioxidant enzyme expression through epigenetic modification of cardiac myocyte DNA; this is why the protective effect persists for several weeks after a single volatile anesthetic exposure

ANSWER: A

Rationale:

Option A is correct. Anesthetic-induced preconditioning by volatile agents — particularly isoflurane and sevoflurane — is mediated through mechanisms that parallel ischemic preconditioning, a well-established cardioprotective phenomenon. The proposed cellular mechanism involves activation of mitochondrial ATP-sensitive potassium (KATP) channels, which open when cellular energy charge falls and help preserve mitochondrial membrane potential during ischemia, reducing the mitochondrial permeability transition that drives ischemia-reperfusion injury. Adenosine receptor signaling is one pathway linking volatile agent exposure to KATP channel activation. Clinical trials in patients undergoing coronary artery bypass surgery have shown that volatile anesthetic-based maintenance reduces postoperative troponin release — a sensitive marker of myocardial injury — compared to total intravenous anesthesia, though the clinical significance in terms of hard outcomes remains an active area of investigation.

Option B: Option B is incorrect because the preconditioning mechanism is not mediated through mild myocardial depression before bypass; in fact, the protective signal is generated at the cellular level through receptor and channel signaling, not through the hemodynamic effect of reduced contractility.
Option C: Option C is incorrect because while neutrophil-mediated reperfusion injury is a real phenomenon and volatile agents do have some anti-inflammatory effects, inhibition of neutrophil adhesion through endothelial adhesion molecule downregulation is not the primary established mechanism of anesthetic preconditioning, and the 4-hour requirement is not a documented feature of this effect.
Option D: Option D is incorrect because the preconditioning effect is a direct cellular phenomenon, not reducible to systemic hemodynamic effects; studies showing reduced troponin release are controlled for hemodynamic differences, and the effect persists even when systemic vascular resistance changes are accounted for.
Option E: Option E is incorrect because anesthetic preconditioning does not involve permanent epigenetic modification of DNA; the protective effect is transient and related to acute cellular signaling events, not lasting gene expression changes.